<DOC>
	<DOCNO>NCT00524576</DOCNO>
	<brief_summary>To evaluate response additional dose ( challenge dose ) hepatitis B vaccine , give subject receive primary vaccination Engerix™-B vaccine approximately 72-78 month ago . This protocol post deal objective &amp; outcome measure challenge phase . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Challenge Dose Hepatitis B Vaccine Subjects Who Previously Received Engerix™-B Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female receive complete primary vaccination course hepatitis B vaccine primary study Written inform consent obtain subject and/or parent/guardian subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month hepatitis B challenge dose . Use investigational/nonregistered drug vaccine study vaccine within 30 day precede hepatitis B vaccine challenge dose plan use study period . Chronic administration ( 14 day ) immunosuppressant immunemodifying drug within six month prior hepatitis B vaccine challenge dose . Planned administration/ administration vaccine foreseen study protocol period start 30 day hepatitis B vaccine challenge dose end 30 day . Subjects receive additional dose hepatitis B vaccine outside context study primary vaccination course hepatitis B challenge vaccination visit . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Acute chronic , clinically significant hepatic renal functional abnormality , determine physical examination laboratory screen test . Administration immunoglobulins and/or blood product within three month precede hepatitis B vaccine challenge dose plan administration study period ( one month ) . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Persistence</keyword>
	<keyword>Challenge dose</keyword>
</DOC>